Luvadaxistat

Last updated
Luvadaxistat
Luvadaxistat.svg
Clinical data
Other namesNBI-1065844; NBI1065844; TAK-831; TAK831
Legal status
Legal status
  • Investigational
Identifiers
  • 6-[2-[4-(Trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C13H11F3N2O2
Molar mass 284.238 g·mol−1
3D model (JSmol)
  • C1=CC(=CC=C1CCC2=CC(=O)C(=O)NN2)C(F)(F)F
  • InChI=1S/C13H11F3N2O2/c14-13(15,16)9-4-1-8(2-5-9)3-6-10-7-11(19)12(20)18-17-10/h1-2,4-5,7H,3,6H2,(H,17,19)(H,18,20)
  • Key:QBQMUMMSYHUDFM-UHFFFAOYSA-N

Luvadaxistat (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name; NBI-1065844, TAK-831) is an experimental drug that works as a D-amino acid oxidase (DAAO) inhibitor and is supposed to increase NMDA receptor functionality. [1] It is developed to treat Friedrich ataxia [2] and negative symptoms of schizophrenia. [3] [4] [5] As of September 2024, it is in phase 2 clinical trials for schizophrenia, no recent development has been reported for ataxia, and the drug has been discontinued for Friedreich's ataxia. [6]

References

  1. ↑ O’Donnell, Patricio; Dong, Cheng; Murthy, Venkatesha; Asgharnejad, Mahnaz; Du, Xiaoming; Summerfelt, Ann; Lu, Hong; Xu, Lin; Wendland, Jens R.; Dunayevich, Eduardo; Buhl, Derek L.; Litman, Robert; Hetrick, William P.; Hong, L. Elliot; Rosen, Laura B. (June 2023). "The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial". Neuropsychopharmacology. 48 (7): 1052–1059. doi:10.1038/s41386-023-01560-0. ISSN   1740-634X. PMC   10018616 . PMID   36928351.
  2. ↑ Wang, Hao; Norton, Jonathan; Xu, Lin; DeMartinis, Nicholas; Sen, Rohini; Shah, Ankit; Farmer, Jennifer; Lynch, David (June 2021). "Results of a randomized double-blind study evaluating luvadaxistat in adults with Friedreich ataxia". Annals of Clinical and Translational Neurology. 8 (6): 1343–1352. doi:10.1002/acn3.51373. PMC   8164851 . PMID   34018342.
  3. ↑ Fradley, Rosa; Goetghebeur, Pascal; Miller, David; Burley, Russell; Almond, Sarah; Gruart i Massó, Agnès; Delgado García, José M.; Zhu, Bin; Howley, Eimear; Neill, Jo C.; Grayson, Ben; Gaskin, Philip; Carlton, Mark; Gray, Ian; Serrats, Jordi; Davies, Ceri H. (October 2023). "Luvadaxistat: A Novel Potent and Selective d-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia". Neurochemical Research. 48 (10): 3027–3041. doi:10.1007/s11064-023-03956-2. PMC   10471729 . PMID   37289348.
  4. ↑ Veselinović, Tanja; Neuner, Irene (August 2022). "Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia". CNS Drugs. 36 (8): 819–858. doi:10.1007/s40263-022-00935-z. PMC   9345797 . PMID   35831706.
  5. ↑ Kuo, Chien-Yi; Lin, Chieh-Hsin; Lane, Hsien-Yuan (November 2022). "Targeting d-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research". CNS Drugs. 36 (11): 1143–1153. doi:10.1007/s40263-022-00959-5. PMID   36194364. S2CID   252694226.
  6. ↑ "Luvadaxistat". AdisInsight. 18 September 2024. Retrieved 4 November 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.